The Janus kinase inhibitor baricitinib, in combination with narrowband ultraviolet B therapy, improved vitiligo, according to ...

If you’re under age 12, we don’t have any drug that is specifically indicated,” Dr. Lawrence F. Eichenfield said.

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

Combining ultraviolet (UV) phototherapy with the Janus kinase (JAK) inhibitor baricitinib (Olumiant) helped patients with ...

This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes ...

TDM-180935 is a topical Janus kinase (JAK)-1/tyrosine kinase (TYK)-2 inhibitor ointment that has previously completed a phase 1 study that showed excellent toleration and minimal systemic ...

The primary outcome of the study was the attainment of low disease activity at week 12, defined as a C-reactive protein (CRP) polymyalgia rheumatica activity score (PMR-AS) of 10 or less without oral ...

For years now, investigators have been studying the Janus kinase (JAK) inhibitor in combination with other drugs, both in first-line treatment and refractory disease. Abstracts and oral ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol amendment proposal presented by Novartis to study ...

JAK inhibitors have since emerged as a promising ... et al "Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: A population-based cohort ...